Jubilant and Orion ink "Hybrid and Integrated" Drug Discovery Collaboration
Jubilant Organosys Ltd, headquartered in Noida, announced today that its subsidiaries Jubilant Biosys Ltd (Bangalore based) and Jubilant Chemsys Ltd (Noida based) have entered into three way drug discovery partnership with Orion, a leading pharmaceutical company of Finland.
Tweet-- Jubilant Organosys Ltd, headquartered in Noida, announced today that its subsidiaries Jubilant Biosys Ltd (Bangalore based) and Jubilant Chemsys Ltd (Noida based) have entered into three way drug discovery partnership with Orion, a leading pharmaceutical company of Finland. Under this “Hybrid & Integrated” arrangement, Orion will have the option of utilizing resources flexibly from both Jubilant Biosys Ltd and Jubilant Chemsys Ltd based on the requirements of its drug discovery projects.
Commenting on the development, Sri Mosur, CEO & President, Jubilant Biosys, said, "We are very pleased to partner with Orion and offer our integrated Discovery services enabling the discovery efforts at Orion. Jubilant's Flexible and Hybrid platform of innovative discovery chemistry, biology and insilico services demonstrates its ability to customize and accelerate global drug discovery efforts. It will be our continued endeavor to enable creative partnering models supporting our scientific capabilities.”
This arrangement bears testimony to the expertise of Jubilant Biosys and Chemsys scientists. A strong team comprising Biologists and Chemists will be engaged in carrying out research on Orion’s projects at the two subsidiaries as per the need of the projects.
Expressing their pleasure with the partnership, Dr Antti Haapalinna, Vice President, Research, R&D of Orion Corporation said," We are happy to partner with Jubilant and are confident of scaling up our drug discovery programs with support from their scientific team. Through this partnership, we would achieve a good basis for success as it would complement our in-house discovery effort."